Pharmacodynamic analyses in a multi-laboratory network: lessons from the poly(ADP-ribose) assay.
Clinical pharmacodynamic assays need to meet higher criteria for sensitivity, precision, robustness, and reproducibility than those expected for research-grade assays because of the long duration of clinical trials and the potentially unpredictable number of laboratories running the assays. This report describes the process of making an immunoassay based on commercially available reagents "clinically ready". The assay was developed to quantify poly(ADP-ribose) (PAR) levels as a marker of PAR polymerase inhibitor activity for a proof-of-concept phase 0 clinical trial at the National Cancer Institute (NCI) and subsequent clinical trials. In this publication, we retrospectively examine the measures taken to validate the published PAR immunoassay and outline key lessons learned during the development and implementation of these procedures at both internal and external clinical trial sites; these measures included optimizing PAR measurements in tumor biopsies and peripheral blood mononuclear cells (PBMCs), reagent qualification, analytical validation and assay quality control, instrument qualification and method quality control, and support for external laboratories.
Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD. Electronic address: Katherine.FerryGalow@nih.gov.
Katherine V
KV
Ferry-Galow
Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD.
Jiuping
J
Ji
Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD.
Robert J
RJ
Kinders
Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD.
Yiping
Y
Zhang
University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA.
R Kenneth
RK
Czambel
University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA.
John C
JC
Schmitz
City of Hope Beckman Research Institute, Duarte, CA.
Josef
J
Herzog
Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD.
Yvonne A
YA
Evrard
Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD.
Ralph E
RE
Parchment
D000818:Animals; D001706:Biopsy / Q000379:methods; D006801:Humans; D007118:Immunoassay / Q000295:instrumentation / Q000379:methods / Q000592:standards; D007202:Indicators and Reagents; D007753:Laboratories; D049449:Luminescence; D051379:Mice; D054547:National Cancer Institute (U.S.); D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000493:pharmacokinetics*; D011065:Poly(ADP-ribose) Polymerases / Q000032:analysis*; D011786:Quality Control; D015203:Reproducibility of Results; D014481:United States; D023041:Xenograft Model Antitumor Assays
D007202:Indicators and Reagents; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases
Assay quality control; Poly(ADP-ribose), PAR; Reagent qualification